biotech
biotech Articles
Oncobiologics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
These biotech companies stood out from the rest with big moves over the course of the past week.
Published:
Last Updated:
Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above water this year.
Published:
Last Updated:
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
Published:
Last Updated:
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
Published:
Last Updated:
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Last Updated:
Beigene has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Published:
Last Updated:
Celgene Corp. (NASDAQ: CELG) sank in Monday's session after providing a business update that was largely in line with analyst expectations.
Published:
Last Updated:
Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.
Published:
Last Updated:
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to be the farthest along and offer the best chance for approval.
Published:
Affymetrix was absolutely soaring early on Monday on word that it will be acquired. Thermo Fisher Scientific is the buyer.
Published:
Last Updated:
Ardelyx recently filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
Published:
Last Updated:
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency this year.
Published:
Last Updated: